Polycythemia Vera Evolution to Chronic Myelomocytic Leukemia: The Prognostic Value of Next Generation Sequencing

María Luisa López Huguet(Universitat Autònoma de Barcelona), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Isabel Granada(Josep Carreras Leukaemia Research Institute), Marco A. Fernández(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Gustavo Tapia(Hospital Universitari Germans Trias i Pujol), Lurdes Zamora(Universitat Autònoma de Barcelona), Marc Sorigué(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Alba Mesa(Universitat Autònoma de Barcelona), Elisa Orna(Universitat Autònoma de Barcelona)
HemaSphere
September 1, 2020
10.1097/hs9.0000000000000466
Cited by 5

Related Papers

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
|Blood|2010|233
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
|Haematologica|2011|215
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
|Blood|2013|189
Human immunodeficiency virus‐associated plasmablastic lymphoma
|Cancer|2012|178